Antithrombin-lowering in hemophilia: a closer look at fitusiran

Fitusiran, C78H139N11O30

Antithrombin-lowering in hemophilia: a closer look at fitusiran - Research and Practice in Thrombosis and Haemostasis

RNAi for the treatment of people with hemophilia

RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A: Molecular Therapy - Nucleic Acids

RNAi for the treatment of people with hemophilia

CME: Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A - AXISMedEd

Pharmaceuticals, Free Full-Text

Dosing of Fitusiran in U.S. Hemophilia Trials to Resume

Frontiers Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications

Antithrombin-lowering in hemophilia: a closer look at fitusiran - ScienceDirect

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial - The Lancet